

Traging Agent: MMPSense680 1.00 0.75 0.50 0.25 0.00 CountEnergy Asthma group:4-1

Ovalbumin-induced Asthma Model; Imaged with FMT 2500 + MMPSense 680

HUMAN HEALTH | ENVIRONMENTAL HEALTH

Fluorescence Molecular Tomography (FMT) Imaging Technology& applications

Pre-clinical Imaging Solutions

February 20, 2019


曾筱筑 產品應用專員

博克科技有限公司 J&H Technology Co., Ltd. http://www.jnhtech.com.tw




Governed by:

- Scattering
- Absorption
- •Tissue Autofluorescence
- Deep tissue signal



Advantages of Imaging in the NIR Spectrum





The absorption spectrum for tissue in the visible and near infrared (NIR) regions



•1,2, or 4 Channel; 635, 680, 750, 790 nm




FMT 2500" LX

Quantitative Tomography In Vivo Imaging System



Step 1: FMT Data Generation


- Reflectance Fluorescence Reference Image Acquired using LEDs
- Transillumination FMT Raster Scan using 80 mW lasers
- Tomographic Data Collected using a 512 x 512 pixel Thermoelectrically Cooled CCD Camera





Step 2: FMT Normalization


Process all paired Absorption and Fluorescence acquisition data to generate normalized fluorescence measurements





Step 3: FMT Reconstruction

Fluorescence quantified to the picomole at each point in the subject, including deep tissue targets





<u>第一頁:Experiment</u>

e Edit Database Agents Hardware DICOM Tools Help	
eriment Scan Ånalysis stabase: Install test 14Apr11	VM675 using CatB680 Fast calib in phantom
Group/Subject/Scan Agent(s)/Dosage Created A Recon RDIs Comp. Description	
Composition MMPSense 680 4/14/2011 2:13 PM	New Study Group(s).
	New Subject
	Reassign
欠約答理 国 方 当・	Remove Subject(s)
資料管理層次為:	Restore Subject(s)
	Delete Item(s)
Database \rightarrow Study \rightarrow Group \rightarrow Subject \rightarrow Scan	
可依照實驗項目、處理或日期分類。	Group
可依照實驗項目、處理或日期分類。	Group 。
可依照實驗項目、處理或日期分類。	Group °
可依照實驗項目、處理或日期分類。	Group °
可依照實驗項目、處理或日期分類。	Group ∘
可依照實驗項目、處理或日期分類。	Group 。
可依照實驗項目、處理或日期分類。	Group ∘
可依照實驗項目、處理或日期分類。 完成Database及Study的新增後,點右方 New Study	Group •
可依照實驗項目、處理或日期分類。 完成Database及Study的新增後,點右方 New Study	Group 。
可依照實驗項目、處理或日期分類。 完成Database及Study的新增後,點右方 New Study	Group 。
可依照實驗項目、處理或日期分類。 完成Database及Study的新增後,點右方 New Study	Group 。
可依照實驗項目、處理或日期分類。 完成Database及Study的新增後,點右方 New Study。	Group •
可依照實驗項目、處理或日期分類。 完成Database及Study的新增後,點右方 New Study	Group 。
可依照實驗項目、處理或日期分類。 完成Database及Study的新增後,點右方 New Study(^{Vew Thurbrals}	Group 。
Database → Study → Group → Subject → Scan 可依照實驗項目、處理或日期分類。 完成Database及Study的新增後,點右方 New Study ////////////////////////////////////	Group 。




💁 Install test 14Apr11 - Test 0414 by Geri - TrueQuant	開始掃之前點這
	而知道之前而是
Experiment Scan Analysis	
Database: Install test 14Apr11 🔹 Study: Test 0414 by Geri 🔹 Rename Study New Study Study Description: VM675 using CatB680 Fast callb in phantom	
Group/Subject/Scan Agent(s)/Dosage Created / Recon ROIs Comp. Description 0114 (N=1) MMPSense 680 4/14/2011 2:13 PM 4/14/2011 2:13 PM 	
Image Display Options ■ Show Boundary ■ Excit Fluor ↓ Excit Fluor ↓ et ■ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓	



Name Sub Ch 635 Age	ents Ch 680 Agents Ch 750 Agents Ch 790 Agents	Description
		Description
New Duplicate Edit	Remove	OK Cancel
出使用的agent	New Study Group Name: Subjects: Description: Agents Channel 635 nm Channel 635 nm VivoT ag 645 conjugate AngioSPARK 680 AngioSPARK 680 Cat B 680 FAST Channel 750 nm Cat 8 750 FAST Cat 8 750 FAST GastroSense 750	ate


11

<u> 第二頁:Scan</u>







Elle Edit Database Agents Hardware DIGOM Tools Help Experiment Scan Analysis Analysis Analysis Analysis	
Select Subject - 0414 - Subject 1: 2 scan(s) - Test Cat8 - Subject 1: - Subject 1	
Scan Description	
Dosage Reflectance Image	選agent
Scan Settings Imaging cassette depth	▲ 先按 capture照一下老鼠位子
Advanced Display Options ✓ Show Scanfield Excit Fluor Initiate Scan Options ● Excitation ● Excitation ● Show Soundaw	(IFD 可目光)
✓ Show Boundary ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ <td></td>	








eriment Scan Analysis	Agents Hard <u>w</u> are DI⊆OM <u>T</u> ools <u>H</u> el			
•			Select Subject - 0414 - Subject 1: 2 scan(s) - Test CatB - Subject 1: 1 scan(s) - Scan 1 4/14/2011	
			- Scan Description	
Show Scanfield	tefl. Image Mix Scan Image Colormap	Scan Image Display Excitation Fluorescence Image Number 48	Initiate Scan Imitiate Scan Imitiate Scan Scan	
			正在 normalization 準備產生 data	








17


<u>第三頁:Analysis</u>






















PerkinElmer For the Better



HUMAN HEALTH | ENVIRONMENTAL HEALTH




PerkinElmer Pre-clinical *In Vivo* Imaging Agents

February 20, 2019

Agent Platforms: Robust Readouts In Vivo






In Vivo Imaging Agent Platforms:




Agent Categories





- > A range of highly fluorescent Physiologic Agents
- Remain stable and localized in the anatomy for various periods of time
- > Always fluorescent, circulate with blood or move through GI tract
 - Designed for in vivo use
 - Limited in vitro applications



Monitor the integrity of the vascular system




AngioSense	Agent that remains localized in vasculature for 0-4 h; accumulates in tumours and arthritic joints at 24 h.	 Angiogenesis Arthritis Cardiovascular Infectious Inflammation Oncology Pulmonary Neurological Vascular
AngioSPARK	Pegylated fluorescent nanoparticles (5 doses); remains localized in vasculature.	 Arthritis Atherosclerosis Hypertension Inflammation Oncology Neurological Vascular
Genhance	Small molecule fluorescence agent. Use as a control or in vascular permeability imaging.	• Vascular
Superhance	Small molecule agent. Binds to albumin in blood for extended (30 m-1 h) vascular imaging.	 Angiogenesis Arthritis Inflammation Neurological
GastroSense	Agent to monitor gastric emptying and the impact of various drugs on gastric motility.	 Gastric Emptying Anatomical reference marker for the gastrointestinal tract

Monitor the integrity of the vascular system



Optimized agents that actively target and bind to specific biomarkers

- Designed for *in vivo* use
- Emerging In vitro applications





Target specific biomarkers

Targeted Agents – Target Biology

	•
Perkin	Elmer [*] For the Better

Agent	Binds to…
BombesinRSense	Bombesin receptors
HER2Sense	Her2/Neu Receptor
FolateRSense	Folate Receptor
TlectinSense	Vascular endothelial cell
OsteoSense	hydroxyapatite
IntegriSense	integrin αvβ3
BacteriSense	Negatively charged phospholipids in Bacterial membrane
Annexin Vivo	Phosphatidylserine during early apoptosis
HypoxiSense	Carbonic Anhyfrase IX in hypoxic tissue and cells
COX-2 Probe	Cyclooxygenase-2 (COX-2)
2-DG	Glucose uptake Imaging
Transferrin-Vivo	Transferrin receptors (TfRs)





HER2/Neu+ tumor targeting by HER2Sense 645

Target specific biomarkers

Targeted Agents – application




agent	application
IntegriSense	 Angiogenesis Atherosclerosis Oncology Neurological
Annexin-Vivo	 Apoptosis Atherosclerosis Inflammation Oncology Neurological
OsteoSense	 Arthritis • Atherosclerosis Bone Turnover • Skeletal Oncology
HypoxiSense	 Oncology
FolateR-Sense	 cancer and inflammation
BacteriSense	 infection
Transferrin-Vivo	Oncology Inflammation

Target specific biomarkers

- Activatable Agents
 - Protein type
 - "Quenched" in their native state
 - Activated by a select panel of disease-associated proteases
 - Designed for in vivo use
 - Emerging In vitro applications





Monitor protease activity associated with disease state



ProSense	Activated by cathepsin B, L, S and plasmin
ProSense Control	Non-activatable analog of ProSense for use as a negative control
ProSense FAST	FAST version of ProSense, with faster kinetics and a broader imaging window.
Cat B FAST	Cathepsin B selective FAST activatable agent
Cat K FAST	Cathepsin K selective FAST activatable agent
MMPSense	Activated by MMP (matrix metalloproteinases, including MMP-2, - 3, -9 and -13)
MMPSense FAST	MMP FAST activatable agent
Neutrophil Elastase FAST	Activated by elastase produced by neutrophil cells using FAST
ReninSense FAST	A renin-angiotensin FAST activatable agent

Monitor protease activity associated with disease state



ProSense	● Arthritis ● Oncology
ProSense Control	Negative control in Arthritis Oncology
ProSense FAST	● Oncology ● Inflammation
Cat B FAST	Cardiovascular disease Oncology Inflammation Certain neurological diseases
Cat K FAST	 Oncology applications involving metastasis to the bone Broad range of bone applications including osteoporosis and bone changes following arthritis
MMPSense	• Oncology
MMPSense FAST	Oncology Inflammation Pulmonary Cardiovascular disease
Neutrophil Elastase FAST	 Acute lung Injury Models Acute respiratory distress syndrome Emphysema Cystic Fibrosis COPD Wound Healing Rheumatoid Arthritis Ischemia-reperfusion
ReninSense FAST	 Cardiovascular disease Certain models of impaired renal function Chronic hyperthyroidism Hypertension Some neurological diseases

Monitor protease activity associated with disease state



PerkinElmer offers four categories of fluorescent *IN VIVO* imaging agents:

LABELS and NANOPARTICLES


VivoTag™ 680XL Protein Labeling Kit : designed for

preparing fluorescently labeled antibodies, proteins or peptides for small animal in vivo imaging applications.

VivoTrack 680 : cell labeling agent that intercalates into the plasma membrane of primary cells and cell lines.

How to perform the experiment?

- 4T1 Mouse Breast Adenocarcinoma Cells
- IV Tail Injection of 0.5 5 x 10⁵ Cells
- BALB/c Mice




37



Assessments:



FMT Imaging of Tumor Cathepsin Activity



FMT and ProSense detect tumor-associated protease activity non-invasively in living animals
 ENT results a graduated well with Lung Waight response activity.


FMT results correlated well with Lung Weight measurements

4T1 Breast Cancer Lung Colonization Model and Therapeutic Response



Quantification of 5-Fluorouracil/2'-deoxyinosine (5-FU/2DI) with ProSense® 750

Whole animal FMT




 FMT and ProSense successfully monitors prophylactic treatment in deep tissue compartments non-invasively
 Total fluorescence showed the greatest sensitivity in drug efficacy


Using Functional Fluorescent Probe to Detect Infection



Detecting thigh infection of Pseudomonas Xen5



RediJect Bacterial Detection Probe 750




ex745nm,em800nm


In vivo imaging of S. epidermidis infections



- SKH-1 E female mice, aged 6-8 weeks, were injected IM with 10⁸ CFUs of S. Epidermidis in the flank region.
- 24 hours after bacteria injection, mice were injected with 5 nmoles of VM3235
- 1, 2, & 3 hours following agent injection, mice were imaged on the 3D fluorescence Imaging with emphasis on the flank area




Tomography



In Vivo Imaging of E. Coli Infection




- 18 SKH-1 E female mice, aged 6-8 weeks, were injected IM with 1 x 10⁸ CFUs of E. coli in the flank region.
- 24 hours after bacteria injection, mice were injected with 5 nmoles of VM3235
- 1 hour following agent injection, mice were imaged on the FMT2500 with emphasis on the flank area



Infection-induced inflammation neutrophil infiltration as measured by in vivo fluorescence imaging

43






In vivo detection of Staphylococcus aureus



AF680-ProT (prothrombin derivatives) bound staphylocoagulase




Peter Panizzi et al., nature medicine 2011



CAIA Model : ProSense & Early Disease (Day 4)

- Arthritis is not clinically detectable
- 24 hrs after ProSense probe injection




imaging with ProSense can detect disease at earlier time points, prior to detection by paw thickness

CAIA Model : ProSense & Late Disease (Day 8)



- Arthritis is clinically detectable and at its peak
- 24 hrs after ProSense probe injection




imaging with ProSense provides a 10-fold signal over control animals at the peak of the disease

Anti-inflammatory Treatment of CAIA




Dexamethasone: Days 5 & 6 following Collagen Ab Injection




ProSense correlates well with classical measures but is significant at lower doses



Multiplex FMT Imaging




Vascular Leak



Ovalbumin (OVA)-induced Asthma








Imaging Ovalbumin (OVA)-induced Asthma


In vivo FMT Tomographic Imaging




Asthma lung signal using ProSense is considerably higher and involves a larger volume than in control mice



Steroid inhibition of OVA-induced Asthma



Dexamethasone Therapeutic Activity in Asthma




Perkin

Tomographic images readily show clear differences in asthmatic, treated, and control mice




Dexamethasone Dose Response in Asthma



Cy5.5-labeled AC133.1 antibody





Citation: Tsurumi C, Esser N, Firat E, Gaedicke S, Follo M, et al. (2010) Non-Invasive In Vivo Imaging of Tumor-Associated CD133/Prominin. PLoS ONE 5(12):e15605. doi:10.1371/journal.pone.0015605





Thank you!

For More Information: www.perkinelmer.com J&HTechnology 博克科技有限公司